Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Post-Trial Drug Access
Drugs
Locations
Clinical Specialty
541-560 of 847 trials

Botulinum Toxin for Spastic Equinovarus in Stroke Patients

We are exploring how a treatment with botulinum toxin type A affects muscle and nerve properties in people who have had their first stroke. This study aims to gather insights that could improve future treatments for spastic equinovarus.

Spastic Equinovarus in Stroke Patients3-6 monthsConfirmation phase (III)Monitoring phase (IV)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesNeurologyOrthopedics and Traumatology

Multiple Sclerosis: Personalized Ocrelizumab Treatment

We are studying whether a tailored dosing of ocrelizumab is as effective as the standard treatment in managing relapsing remitting multiple sclerosis. This trial aims to improve treatment personalization for better disease control.

Multiple Sclerosis>2 yearsConfirmation phase (III)Monitoring phase (IV)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteNeurology

Asthma Treatment: Tezepelumab Study

We are investigating whether tezepelumab can improve airway structure and function in patients with asthma compared to a placebo. This study will also explore its effects on lung health and asthma flare-ups.

Severe Asthma3-6 monthsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementAllergologyPulmonology

Axial Spondyloarthritis: NSAIDs vs. Biosimilar TNF Blockers

We are comparing the effectiveness of high-dose NSAIDs and a biosimilar TNF blocker for patients with axial spondyloarthritis who haven't responded to NSAIDs. The study will also look at side effects and inflammation levels.

Axial Spondyloarthritis3-6 monthsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesInternal MedicineRheumatology

Hidradenitis Suppurativa: Remibrutinib Study

We are testing the effectiveness and safety of remibrutinib in adults with moderate to severe hidradenitis suppurativa. The study aims to see if it helps reduce symptoms like flare-ups and skin pain compared to a placebo.

Hidradenitis Suppurativa1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyDermatology

Relapsed or Refractory PCNSL: Emavusertib Study

We are studying the safety and effectiveness of a new oral medication, emavusertib, for patients with relapsed or refractory primary central nervous system lymphoma. This trial also explores its use alongside another treatment, ibrutinib.

Hematological MalignancyPrimary Central Nervous System Lymphoma (PCNSL)Safety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesNeurologyOncology

KCNT1-Related Epilepsy: S230815 Treatment Study

We are testing a new treatment for children with KCNT1-related Developmental and Epileptic Encephalopathy. The study aims to evaluate its safety and how it may help reduce seizure activity.

KCNT1-related Developmental and Epileptic Encephalopathy1-2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

Transfusion-Dependent β-Thalassemia: CTX001 Treatment

We are studying a new cell therapy for children with transfusion-dependent β-thalassemia to see if it can improve their condition and reduce the need for blood transfusions. The trial will also assess the safety of this treatment.

Transfusion-Dependent Thalassemia>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementHematologyPediatrics

BRAF Mutated Melanoma: Encorafenib and Binimetinib with Cemiplimab and Fianlimab

We are studying a combination of treatments for patients with BRAF mutated melanoma and brain metastases. The goal is to see if this approach can help control the disease and improve survival.

Melanoma>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteNeurologyOncology

Parkinson's Disease: BIIB122 Treatment Study

We are studying the safety and effects of BIIB122 in people with LRRK2-associated Parkinson's disease. This trial aims to understand how well the treatment engages important biological pathways.

Parkinson's Disease>2 yearsEfficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesNeurology

Brigatinib for Pediatric and Young Adult ALK+ Cancer

We are studying the safety and effectiveness of brigatinib in children and young adults with ALK+ Anaplastic Large Cell Lymphoma and other solid tumors. This trial aims to find the best dose and understand how the drug works in these patients.

Anaplastic Large Cell Lymphoma (ALCL)Inflammatory Myofibroblastic Tumors (IMT)Other Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncologyPediatrics

Type 2 Diabetes: Comparing Empagliflozin, Pioglitazone, and Semaglutide

We are studying how different diabetes medications affect fat tissue function in people with type 2 diabetes. This research may help us understand which drug works best for improving health outcomes.

Type 2 Diabetes6-12 monthsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteDiabetologyEndocrinology

CSL889 for Sickle Cell Disease: A New Treatment

We are studying the safety and effects of CSL889 in adults and adolescents with sickle cell disease during painful vaso-occlusive crises. The goal is to see if it helps speed up recovery compared to a placebo.

Sickle Cell Anemia with Crisis≤3 monthsEfficacy phase (II)Confirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteHematologyInternal Medicine

Crohn’s Disease and Ulcerative Colitis: Tulisokibart Study

We are studying the long-term safety and effectiveness of tulisokibart in people with Crohn’s disease or ulcerative colitis. This research aims to see how well the treatment helps manage symptoms and achieve remission.

Crohn's DiseaseUlcerative Colitis>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessInvestigational MedicinesGastroenterologyInternal Medicine

Generalized Anxiety Disorder: MM120 Medication Study

We are testing a new oral medication, MM120, to see if it helps reduce anxiety symptoms in adults with generalized anxiety disorder. The study will also look at its effects on quality of life and sexual functioning.

Generalized Anxiety Disorder1-2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemotePsychiatry

YTB323 for Treatment-Resistant Generalized Myasthenia Gravis

We are studying the safety and effects of YTB323 in patients with treatment-resistant generalized myasthenia gravis. This research aims to understand how the drug works in the body and its potential to improve symptoms.

Myasthenia Gravis1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementInternal MedicineNeurology

COPD: Dronabinol for Breathlessness Relief

We are studying whether Dronabinol can help people with severe and very severe COPD experience less breathlessness. This trial will compare its effects against a placebo.

Chronic Obstructive Pulmonary Disease≤3 monthsEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessStandard MedicinesInternal MedicinePulmonology

Pulmonary Arterial Hypertension: LTP001 Treatment Study

We are studying a new treatment called LTP001 in healthy adults and in individuals with pulmonary arterial hypertension. The goal is to evaluate its safety and how well it may improve exercise capacity and overall health.

Pulmonary Arterial HypertensionSafety phase (I)Efficacy phase (II)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyPulmonology

Ataxia Telangiectasia: EryDex Safety Study

We are assessing the safety and tolerability of EryDex in individuals with Ataxia Telangiectasia. Additionally, we’re exploring its potential effects on neurological symptoms.

Ataxia Telangiectasia (A-T)1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteInternal MedicineNeurology

Advanced Solid Tumors: MCLA-158 (Petosemtamab) Study

We are testing a new treatment called MCLA-158 for people with advanced solid tumors to see how well it works and how safe it is. This study looks at its effects alone and in combination with other therapies.

Metastatic Colorectal CancerMalignant Solid TumorSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncology